Gotham Asset Management’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
Other funds holding SRPT
EAM
Gotham Asset Management's SRPT Position: Q2 2026 in Review
Gotham Asset Management sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 47,552 shares — an estimated $1.03M sold.
Gotham Asset Management first reported a position in SRPT in Q3 2017 and held it in 14 quarters. The position peaked at $4.77M in Q4 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Gotham Asset Management reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
- Gotham Asset Management sold 47,552 Sarepta Therapeutics shares in Q2 2026, an estimated $1.03M.
- Gotham Asset Management first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 14 quarters.
- Gotham Asset Management's Sarepta Therapeutics position peaked at $4.77M in Q4 2025.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.